T-Cell Heterogeneity in Baseline Tumor Samples: Implications for Early Clinical Trial Design and Analysis

T-Cell Heterogeneity in Baseline Tumor Samples: Implications for Early Clinical Trial Design and Analysis

BackgroundIn early stage clinical trials, changes to levels of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment (TME) are critical biomarkers of the mechanism of action of novel immunotherapies. However, baseline heterogeneity of tumor samples, both between and within patients, an...

Full description

Bibliographic Details
Main Authors: Laura Brennan, Jurriaan Brouwer-Visser, Eveline Nüesch, Maria Karpova, Astrid Heller, Fabien Gaire, Meike Schneider, Bruno Gomes, Konstanty Korski
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Immunology
Subjects:
IHC – immunohistochemistry
CD8 T-cells
Tregs (regulatory T cells)
tumor infiltrating lymphocytes (TILs)
prior treatment
cancer immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.760763/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.760763/full

Similar Items